NEW YORK (GenomeWeb) – Inform Genomics and Translational Drug Development today announced a collaboration in which TDD will offer Inform's technology and analytic capabilities as part of its drug development services for biopharmaceutical firms. Financial and other terms of the deal were not disclosed.
According to Inform's website, its technology predicts clinical outcomes that physicians and patients can use to make individualized medical decisions. Based on big data storage and memory, and cloud computing technologies, Inform's analytics discover gene-SNP interactions for predicting clinical outcomes. Its lead development program is in support of cancer care, and the company is currently developing two products called OnPart and HSCT/Mucositis to predict a patient's risk for developing common chemotherapy-related side effects.
TDD's "focus on precision oncology solutions, coupled with Inform Genomics' ability to understand individual patient risk for side effects, can give a more complete vision of personalized medicine that has the opportunity to significantly improve patient care," TDD President and CEO Stephen Gately said in a statement.